Foundayo Showed Better Results Than Oral Semaglutide in a New Analysis. There’s a Catch Investors Shouldn’t Miss

insidermonkey.com · 2026-10-06

At the European Association for the Study of Diabetes meeting in Milan, Eli Lilly and Company (NYSE:LLY) presented data showing that its oral GLP-1 pill, Foundayo, delivered greater weight loss and better...

TickrTrends take: Eli Lilly's pipeline strength in obesity and diabetes treatment represents a significant asset base that supports the company's current undervalued positioning within the Healthcare sector. The competitive dynamics between injectable and oral formulations in the semaglutide market category will influence the commercial potential of Lilly's GLP-1 portfolio and its ability to capture market share. Investors monitoring Lilly's valuation should track clinical and commercial developments that could affect the company's revenue growth trajectory and competitive positioning relative to its current market price.

Read the full story at insidermonkey.com →